ZHONGXING LIAO to Antineoplastic Combined Chemotherapy Protocols
This is a "connection" page, showing publications ZHONGXING LIAO has written about Antineoplastic Combined Chemotherapy Protocols.
Connection Strength
0.299
-
Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy. BMC Cancer. 2010 Aug 16; 10:431.
Score: 0.075
-
Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence. Int J Radiat Oncol Biol Phys. 2000 Jul 15; 47(5):1191-200.
Score: 0.037
-
Comparison of locoregional versus extended locoregional radiation volumes for patients with nonmetastatic gastro-esophageal junction carcinomas. J Thorac Oncol. 2015 Mar; 10(3):518-26.
Score: 0.026
-
Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012 Dec 01; 84(5):1078-85.
Score: 0.022
-
Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer. Cancer. 2011 Jul 01; 117(13):3004-13.
Score: 0.019
-
Cyclo-oxygenase-2 and its inhibition in cancer: is there a role? Drugs. 2007; 67(6):821-45.
Score: 0.015
-
Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol. 2006 Aug 10; 24(23):3789-98.
Score: 0.014
-
Twice daily irradiation increases locoregional control in patients with medically inoperable or surgically unresectable stage II-IIIB non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002 Jul 01; 53(3):558-65.
Score: 0.011
-
Mantle irradiation alone for pathologic stage I and II Hodgkin's disease: long-term follow-up and patterns of failure. Int J Radiat Oncol Biol Phys. 2001 Jul 15; 50(4):971-7.
Score: 0.010
-
Mucosa-associated lymphoid tissue lymphoma with initial supradiaphragmatic presentation: natural history and patterns of disease progression. Int J Radiat Oncol Biol Phys. 2000 Sep 01; 48(2):399-403.
Score: 0.009
-
Giant Circulating Cancer-Associated Macrophage-Like Cells Are Associated With Disease Recurrence and Survival in Non-Small-Cell Lung Cancer Treated With Chemoradiation and Atezolizumab. Clin Lung Cancer. 2021 05; 22(3):e451-e465.
Score: 0.009
-
Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. J Thorac Oncol. 2020 02; 15(2):248-257.
Score: 0.009
-
The relationship of lymphocyte recovery and prognosis of esophageal cancer patients with severe radiation-induced lymphopenia after chemoradiation therapy. Radiother Oncol. 2019 04; 133:9-15.
Score: 0.008
-
Factors Predictive of Improved Outcomes With Multimodality Local Therapy After Palliative Chemotherapy for Stage IV Esophageal Cancer. Am J Clin Oncol. 2016 06; 39(3):228-35.
Score: 0.007
-
Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer. Radiother Oncol. 2015 Jun; 115(3):367-72.
Score: 0.007
-
Propensity score-matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front-line chemotherapy. Int J Radiat Oncol Biol Phys. 2014 Nov 15; 90(4):850-7.
Score: 0.006
-
Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer. Ann Surg Oncol. 2014 Jan; 21(1):306-14.
Score: 0.006
-
Predictors of postoperative complications after trimodality therapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2013 Aug 01; 86(5):885-91.
Score: 0.006
-
Equivalent outcome of patients with clinical Stage IIIA non-small-cell lung cancer treated with concurrent chemoradiation compared with induction chemotherapy followed by surgical resection. Int J Radiat Oncol Biol Phys. 2004 Jan 01; 58(1):204-12.
Score: 0.003